世界のアドレノミロニューロパシー治療市場2020年:企業別、地域別、種類・用途別

【英語タイトル】Global Adrenomyeloneuropathy Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが出版した調査資料(GIR20SP03151)・商品コード:GIR20SP03151
・発行会社(調査会社):GlobalInfoResearch
・発行日:2020年9月18日(※2024年版があります。お問い合わせください)
・ページ数:109
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、アドレノミロニューロパシー治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。アドレノミロニューロパシー治療の種類別市場規模(ステロイド補充療法、幹細胞移植)、用途別市場規模(病院、クリニック、外来手術センター、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Ascend Biopharmaceuticals、Immatics Biotechnologies、Human Longevity、Novadip Biosciences、BioRestorative Therapies、Eureka Therapeutics、Cytori Therapeutics、Allogene Therapeutics、Regeneus、NewLink Genetics、Talaris Therapeutics
・地域別グローバル市場分析 2015年-2020年
・アドレノミロニューロパシー治療の北米市場(アメリカ、カナダ、メキシコ)
・アドレノミロニューロパシー治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・アドレノミロニューロパシー治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・アドレノミロニューロパシー治療の南米市場(ブラジル、アルゼンチン)
・アドレノミロニューロパシー治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:ステロイド補充療法、幹細胞移植
・用途別分析:病院、クリニック、外来手術センター、その他
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The Adrenomyeloneuropathy Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Adrenomyeloneuropathy Treatment sales will be xx in 2020 from Adrenomyeloneuropathy Treatment million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Adrenomyeloneuropathy Treatment market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Adrenomyeloneuropathy Treatment industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Adrenomyeloneuropathy Treatment and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Adrenomyeloneuropathy Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Adrenomyeloneuropathy Treatment market has been segmented into:
Steroid Replacement Therapy
Stem Cell Transplant

By Application, Adrenomyeloneuropathy Treatment has been segmented into:
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Adrenomyeloneuropathy Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Adrenomyeloneuropathy Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Adrenomyeloneuropathy Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Adrenomyeloneuropathy Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Adrenomyeloneuropathy Treatment Market Share Analysis
Adrenomyeloneuropathy Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Adrenomyeloneuropathy Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Adrenomyeloneuropathy Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Adrenomyeloneuropathy Treatment are:
Ascend Biopharmaceuticals
Immatics Biotechnologies
Human Longevity
Novadip Biosciences
BioRestorative Therapies
Eureka Therapeutics
Cytori Therapeutics
Allogene Therapeutics
Regeneus
NewLink Genetics
Talaris Therapeutics
Among other players domestic and global, Adrenomyeloneuropathy Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

【レポートの目次】

1 Adrenomyeloneuropathy Treatment Market Overview
1.1 Product Overview and Scope of Adrenomyeloneuropathy Treatment
1.2 Classification of Adrenomyeloneuropathy Treatment by Therapy
1.2.1 Global Adrenomyeloneuropathy Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Adrenomyeloneuropathy Treatment Revenue Market Share by Therapy in 2019
1.2.3 Steroid Replacement Therapy
1.2.4 Stem Cell Transplant
1.3 Global Adrenomyeloneuropathy Treatment Market by End Users
1.3.1 Overview: Global Adrenomyeloneuropathy Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Global Adrenomyeloneuropathy Treatment Market by Regions
1.4.1 Global Adrenomyeloneuropathy Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Adrenomyeloneuropathy Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Adrenomyeloneuropathy Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Adrenomyeloneuropathy Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Adrenomyeloneuropathy Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Adrenomyeloneuropathy Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Adrenomyeloneuropathy Treatment Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Adrenomyeloneuropathy Treatment Industry Impact
1.5.1 COVID-19 Potential Implications for the Adrenomyeloneuropathy Treatment
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Adrenomyeloneuropathy Treatment
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Ascend Biopharmaceuticals
2.1.1 Ascend Biopharmaceuticals Details
2.1.2 Ascend Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Ascend Biopharmaceuticals SWOT Analysis
2.1.4 Ascend Biopharmaceuticals Product and Services
2.1.5 Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Immatics Biotechnologies
2.2.1 Immatics Biotechnologies Details
2.2.2 Immatics Biotechnologies Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Immatics Biotechnologies SWOT Analysis
2.2.4 Immatics Biotechnologies Product and Services
2.2.5 Immatics Biotechnologies Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Human Longevity
2.3.1 Human Longevity Details
2.3.2 Human Longevity Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Human Longevity SWOT Analysis
2.3.4 Human Longevity Product and Services
2.3.5 Human Longevity Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novadip Biosciences
2.4.1 Novadip Biosciences Details
2.4.2 Novadip Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novadip Biosciences SWOT Analysis
2.4.4 Novadip Biosciences Product and Services
2.4.5 Novadip Biosciences Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 BioRestorative Therapies
2.5.1 BioRestorative Therapies Details
2.5.2 BioRestorative Therapies Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 BioRestorative Therapies SWOT Analysis
2.5.4 BioRestorative Therapies Product and Services
2.5.5 BioRestorative Therapies Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Eureka Therapeutics
2.6.1 Eureka Therapeutics Details
2.6.2 Eureka Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Eureka Therapeutics SWOT Analysis
2.6.4 Eureka Therapeutics Product and Services
2.6.5 Eureka Therapeutics Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Cytori Therapeutics
2.7.1 Cytori Therapeutics Details
2.7.2 Cytori Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Cytori Therapeutics SWOT Analysis
2.7.4 Cytori Therapeutics Product and Services
2.7.5 Cytori Therapeutics Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Allogene Therapeutics
2.8.1 Allogene Therapeutics Details
2.8.2 Allogene Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Allogene Therapeutics SWOT Analysis
2.8.4 Allogene Therapeutics Product and Services
2.8.5 Allogene Therapeutics Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Regeneus
2.9.1 Regeneus Details
2.9.2 Regeneus Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Regeneus SWOT Analysis
2.9.4 Regeneus Product and Services
2.9.5 Regeneus Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 NewLink Genetics
2.10.1 NewLink Genetics Details
2.10.2 NewLink Genetics Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 NewLink Genetics SWOT Analysis
2.10.4 NewLink Genetics Product and Services
2.10.5 NewLink Genetics Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.11 Talaris Therapeutics
2.11.1 Talaris Therapeutics Details
2.11.2 Talaris Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Talaris Therapeutics SWOT Analysis
2.11.4 Talaris Therapeutics Product and Services
2.11.5 Talaris Therapeutics Adrenomyeloneuropathy Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Adrenomyeloneuropathy Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Adrenomyeloneuropathy Treatment Players Market Share
3.2.2 Top 10 Adrenomyeloneuropathy Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Adrenomyeloneuropathy Treatment Revenue and Market Share by Regions
4.2 North America Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
5 North America Adrenomyeloneuropathy Treatment Revenue by Countries
5.1 North America Adrenomyeloneuropathy Treatment Revenue by Countries (2015-2020)
5.2 USA Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
6 Europe Adrenomyeloneuropathy Treatment Revenue by Countries
6.1 Europe Adrenomyeloneuropathy Treatment Revenue by Countries (2015-2020)
6.2 Germany Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
6.4 France Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Adrenomyeloneuropathy Treatment Revenue by Countries
7.1 Asia-Pacific Adrenomyeloneuropathy Treatment Revenue by Countries (2015-2020)
7.2 China Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
7.5 India Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
8 South America Adrenomyeloneuropathy Treatment Revenue by Countries
8.1 South America Adrenomyeloneuropathy Treatment Revenue by Countries (2015-2020)
8.2 Brazil Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Adrenomyeloneuropathy Treatment by Countries
9.1 Middle East & Africa Adrenomyeloneuropathy Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Adrenomyeloneuropathy Treatment Revenue and Market Share by Therapy (2015-2020)
10.2 Global Adrenomyeloneuropathy Treatment Market Forecast by Therapy (2019-2024)
10.3 Steroid Replacement Therapy Revenue Growth Rate (2015-2025)
10.4 Stem Cell Transplant Revenue Growth Rate (2015-2025)
11 Global Adrenomyeloneuropathy Treatment Market Segment by End Users
11.1 Global Adrenomyeloneuropathy Treatment Revenue Market Share by End Users (2015-2020)
11.2 Adrenomyeloneuropathy Treatment Market Forecast by End Users (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Adrenomyeloneuropathy Treatment Market Size Forecast (2021-2025)
12.1 Global Adrenomyeloneuropathy Treatment Market Size Forecast (2021-2025)
12.2 Global Adrenomyeloneuropathy Treatment Market Forecast by Regions (2021-2025)
12.3 North America Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
12.6 South America Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Adrenomyeloneuropathy Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Adrenomyeloneuropathy Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Adrenomyeloneuropathy Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Adrenomyeloneuropathy Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Adrenomyeloneuropathy Treatment Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Ascend Biopharmaceuticals Corporate Information, Location and Competitors
Table 7. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Major Business
Table 8. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 9. Ascend Biopharmaceuticals SWOT Analysis
Table 10. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Product and Solutions
Table 11. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Immatics Biotechnologies Corporate Information, Location and Competitors
Table 13. Immatics Biotechnologies Adrenomyeloneuropathy Treatment Major Business
Table 14. Immatics Biotechnologies Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2018-2019)
Table 15. Immatics Biotechnologies SWOT Analysis
Table 16. Immatics Biotechnologies Adrenomyeloneuropathy Treatment Product and Solutions
Table 17. Immatics Biotechnologies Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Human Longevity Corporate Information, Location and Competitors
Table 19. Human Longevity Adrenomyeloneuropathy Treatment Major Business
Table 20. Human Longevity Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 21. Human Longevity SWOT Analysis
Table 22. Human Longevity Adrenomyeloneuropathy Treatment Product and Solutions
Table 23. Human Longevity Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Novadip Biosciences Corporate Information, Location and Competitors
Table 25. Novadip Biosciences Adrenomyeloneuropathy Treatment Major Business
Table 26. Novadip Biosciences Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 27. Novadip Biosciences SWOT Analysis
Table 28. Novadip Biosciences Adrenomyeloneuropathy Treatment Product and Solutions
Table 29. Novadip Biosciences Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. BioRestorative Therapies Corporate Information, Location and Competitors
Table 31. BioRestorative Therapies Adrenomyeloneuropathy Treatment Major Business
Table 32. BioRestorative Therapies Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 33. BioRestorative Therapies SWOT Analysis
Table 34. BioRestorative Therapies Adrenomyeloneuropathy Treatment Product and Solutions
Table 35. BioRestorative Therapies Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Eureka Therapeutics Corporate Information, Location and Competitors
Table 37. Eureka Therapeutics Adrenomyeloneuropathy Treatment Major Business
Table 38. Eureka Therapeutics Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 39. Eureka Therapeutics SWOT Analysis
Table 40. Eureka Therapeutics Adrenomyeloneuropathy Treatment Product and Solutions
Table 41. Eureka Therapeutics Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Cytori Therapeutics Corporate Information, Location and Competitors
Table 43. Cytori Therapeutics Adrenomyeloneuropathy Treatment Major Business
Table 44. Cytori Therapeutics Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 45. Cytori Therapeutics SWOT Analysis
Table 46. Cytori Therapeutics Adrenomyeloneuropathy Treatment Product and Solutions
Table 47. Cytori Therapeutics Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Allogene Therapeutics Corporate Information, Location and Competitors
Table 49. Allogene Therapeutics Adrenomyeloneuropathy Treatment Major Business
Table 50. Allogene Therapeutics Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 51. Allogene Therapeutics SWOT Analysis
Table 52. Allogene Therapeutics Adrenomyeloneuropathy Treatment Product and Solutions
Table 53. Allogene Therapeutics Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Regeneus Corporate Information, Location and Competitors
Table 55. Regeneus Adrenomyeloneuropathy Treatment Major Business
Table 56. Regeneus Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 57. Regeneus SWOT Analysis
Table 58. Regeneus Adrenomyeloneuropathy Treatment Product and Solutions
Table 59. Regeneus Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. NewLink Genetics Corporate Information, Location and Competitors
Table 61. NewLink Genetics Adrenomyeloneuropathy Treatment Major Business
Table 62. NewLink Genetics Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 63. NewLink Genetics SWOT Analysis
Table 64. NewLink Genetics Adrenomyeloneuropathy Treatment Product and Solutions
Table 65. NewLink Genetics Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Talaris Therapeutics Corporate Information, Location and Competitors
Table 67. Talaris Therapeutics Adrenomyeloneuropathy Treatment Major Business
Table 68. Talaris Therapeutics Adrenomyeloneuropathy Treatment Total Revenue (USD Million) (2017-2018)
Table 69. Talaris Therapeutics SWOT Analysis
Table 70. Talaris Therapeutics Adrenomyeloneuropathy Treatment Product and Solutions
Table 71. Talaris Therapeutics Adrenomyeloneuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) by Players (2015-2020)
Table 73. Global Adrenomyeloneuropathy Treatment Revenue Share by Players (2015-2020)
Table 74. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) by Regions (2015-2020)
Table 75. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Regions (2015-2020)
Table 76. North America Adrenomyeloneuropathy Treatment Revenue by Countries (2015-2020)
Table 77. North America Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Table 78. Europe Adrenomyeloneuropathy Treatment Revenue (Million USD) by Countries (2015-2020)
Table 79. Asia-Pacific Adrenomyeloneuropathy Treatment Revenue (Million USD) by Countries (2015-2020)
Table 80. South America Adrenomyeloneuropathy Treatment Revenue by Countries (2015-2020)
Table 81. South America Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Table 82. Middle East and Africa Adrenomyeloneuropathy Treatment Revenue (Million USD) by Countries (2015-2020)
Table 83. Middle East and Africa Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Table 84. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) by Type (2015-2020)
Table 85. Global Adrenomyeloneuropathy Treatment Revenue Share by Type (2015-2020)
Table 86. Global Adrenomyeloneuropathy Treatment Revenue Forecast by Type (2021-2025)
Table 87. Global Adrenomyeloneuropathy Treatment Revenue by Application (2015-2020)
Table 88. Global Adrenomyeloneuropathy Treatment Revenue Share by Application (2015-2020)
Table 89. Global Adrenomyeloneuropathy Treatment Revenue Forecast by Application (2021-2025)
Table 90. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Adrenomyeloneuropathy Treatment Picture
Figure 2. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Therapy in 2019
Figure 3. Steroid Replacement Therapy Picture
Figure 4. Stem Cell Transplant Picture
Figure 5. Adrenomyeloneuropathy Treatment Revenue Market Share by End Users in 2019
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Ambulatory Surgical Centers Picture
Figure 9. Others Picture
Figure 10. Global Adrenomyeloneuropathy Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Adrenomyeloneuropathy Treatment Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Adrenomyeloneuropathy Treatment Revenue Market Share in 2019
Figure 19. Global Top 10 Players Adrenomyeloneuropathy Treatment Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Regions (2015-2020)
Figure 23. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Regions in 2018
Figure 24. North America Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 25. Europe Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 27. South America Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 29. North America Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Figure 30. North America Adrenomyeloneuropathy Treatment Revenue Market Share by Countries in 2019
Figure 31. USA Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 32. Canada Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Europe Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Adrenomyeloneuropathy Treatment Revenue Market Share by Countries in 2019
Figure 36. Germany Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 37. UK Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 38. France Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 39. Russia Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 40. Italy Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Adrenomyeloneuropathy Treatment Revenue Market Share by Countries in 2019
Figure 43. China Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 44. Japan Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Korea Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 46. India Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 48. South America Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Figure 49. South America Adrenomyeloneuropathy Treatment Revenue Market Share by Countries in 2019
Figure 50. Brazil Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Adrenomyeloneuropathy Treatment Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Adrenomyeloneuropathy Treatment Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 55. UAE Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Adrenomyeloneuropathy Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Global Adrenomyeloneuropathy Treatment Revenue Share by Type (2015-2020)
Figure 59. Global Adrenomyeloneuropathy Treatment Revenue Share by Type in 2019
Figure 60. Global Adrenomyeloneuropathy Treatment Market Share Forecast by Type (2021-2025)
Figure 61. Global Steroid Replacement Therapy Revenue Growth Rate (2015-2020)
Figure 62. Global Stem Cell Transplant Revenue Growth Rate (2015-2020)
Figure 63. Global Adrenomyeloneuropathy Treatment Revenue Share by Application (2015-2020)
Figure 64. Global Adrenomyeloneuropathy Treatment Revenue Share by Application in 2019
Figure 65. Global Adrenomyeloneuropathy Treatment Market Share Forecast by Application (2021-2025)
Figure 66. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 67. Global Clinics Revenue Growth Rate (2015-2020)
Figure 68. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Adrenomyeloneuropathy Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Adrenomyeloneuropathy Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
Figure 74. Europe Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
Figure 76. South America Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Adrenomyeloneuropathy Treatment Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel


【掲載企業】

Ascend Biopharmaceuticals、Immatics Biotechnologies、Human Longevity、Novadip Biosciences、BioRestorative Therapies、Eureka Therapeutics、Cytori Therapeutics、Allogene Therapeutics、Regeneus、NewLink Genetics、Talaris Therapeutics

★調査レポート[世界のアドレノミロニューロパシー治療市場2020年:企業別、地域別、種類・用途別] (コード:GIR20SP03151)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のアドレノミロニューロパシー治療市場2020年:企業別、地域別、種類・用途別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆